Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more
Biovica International AB (publ) - Asset Resilience Ratio
Biovica International AB (publ) (BIOVIC-B) has an Asset Resilience Ratio of 28.69% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Biovica International AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Biovica International AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr16.30 Million | 28.69% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr16.30 Million | 28.69% |
Asset Resilience Insights
- Very High Liquidity: Biovica International AB (publ) maintains exceptional liquid asset reserves at 28.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biovica International AB (publ) Industry Peers by Asset Resilience Ratio
Compare Biovica International AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Biovica International AB (publ) (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Biovica International AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 0.00% | Skr0.00 | Skr64.95 Million | -- |
| 2024-04-30 | 19.55% | Skr25.68 Million | Skr131.41 Million | +5.38pp |
| 2023-04-30 | 14.17% | Skr24.41 Million | Skr172.29 Million | -53.21pp |
| 2022-04-30 | 67.38% | Skr102.17 Million | Skr151.63 Million | -8.08pp |
| 2021-04-30 | 75.46% | Skr145.38 Million | Skr192.65 Million | +30.27pp |
| 2020-04-30 | 45.19% | Skr40.79 Million | Skr90.26 Million | -2.07pp |
| 2019-04-30 | 47.26% | Skr28.76 Million | Skr60.86 Million | -4.89pp |
| 2018-04-30 | 52.16% | Skr42.13 Million | Skr80.77 Million | -15.21pp |
| 2017-04-30 | 67.37% | Skr65.47 Million | Skr97.18 Million | +67.43pp |
| 2016-04-30 | -0.07% | Skr-19.81K | Skr28.73 Million | -- |